GSK2118436 (Dabrafenib) another ATP competitive BRAF inhibitor, has recently shown a dramatic effect as single agent in patients with metastatic melanoma and other solid tumours [143, 153], and is currently under a phase I/II clinical trial [145]. This evidence concerns the gene BRAF and metastatic melanoma.